Description: Invion Limited, a clinical-stage drug development company, develops treatments for chronic inflammatory and autoimmune diseases in Australia and the United States. Its drug candidates in phase II clinical trials include INV102, a beta blocker to treat chronic inflammatory airway diseases, such as asthma and chronic obstructive pulmonary disease; and INV104, a leukotriene receptor antagonist that reduces inflammation, constriction of the airways, and build-up of mucus in the lungs. The company has a research and development alliance agreement with Hudson Institute of Medical Research to collaborate on a range of research and development projects for the Photosoft technology for the treatment of a range of cancers. Invion Limited is based in East Kew, Australia.
Home Page: www.inviongroup.com
100 Albert Road
Melbourne,
VIC
3205
Australia
Phone:
61 3 9692 7222
Officers
| Name | Title |
|---|---|
| Mr. Thian Chew | Executive Chairman & CEO |
| Ms. Melanie Jaye Leydin B.Bus, C.A. | CFO, Company Secretary & Non-Executive Director |
| Dr. Dean Naylor | Head of Intellectual Property Development |
Exchange: PINK
Country: US : United States of America
Currency: US Dollar ($)
| GIC Sector: | Health Care |
|---|---|
| GIC Group: | Pharmaceuticals, Biotechnology & Life Sciences |
| GIC Industry: | Pharmaceuticals |
| GIC Sub-Industry: | Pharmaceuticals |
| Forward PE: | 0 |
|---|---|
| Trailing PE: | 0 |
| Price-to-Book MRQ: | 1.6405 |
| Price-to-Sales TTM: | 4.0594 |
| IPO Date: | |
| Fiscal Year End: | June |
| Full Time Employees: | 0 |